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Background. Herpes simplex virus type 1 (HSV-1) epidemiology in Asia was characterized by assessing seroprevalence levels 
and extent to which HSV-1 is isolated from clinically diagnosed genital ulcer disease (GUD) and genital herpes.
Methods. HSV-1 reports in Asia were systematically reviewed and synthesized, following PRISMA guidelines. Random-effects 
meta-analyses estimated pooled mean seroprevalence and proportion of HSV-1 detection in GUD and genital herpes. Random-
effects meta-regressions identified predictors of seroprevalence and sources of between-study heterogeneity.
Results. Forty-nine relevant publications were identified. Fifty-four overall seroprevalence measures (182 stratified measures), 
and 8 and 24 proportions of HSV-1 detection in GUD and in genital herpes, respectively, were extracted. The pooled mean seroprev-
alence was 50.0% (n = 26; 95% confidence interval [CI], 41.3%–58.7%) for children and 76.5% (n = 151; 73.3%–79.6%) for adults. 
By age group, the pooled mean was lowest at 55.5% (n = 37; 95% CI, 47.5%–63.4%) in individuals aged <20 years, followed by 67.9% 
(n = 48; 62.4%–73.3%) in those aged 20–39 and 87.5% (n = 44; 83.4%–91.1%) in those aged ≥40 years. In meta-regression, age was 
the major predictor of seroprevalence. The mean proportion of HSV-1 detection was 5.6% (n = 8; 95% CI, 0.8%–13.6%) in GUD and 
18.8% (n = 24; 12.0%–26.7%) in genital herpes.
Conclusions. HSV-1 epidemiology is transitioning in Asia. HSV-1 is probably playing a significant role as a sexually transmitted 
infection, explaining one-fifth of genital herpes cases. There is a need for expanded seroprevalence monitoring and GUD/genital 
herpes etiological surveillance.
Keywords. seroprevalence; genital ulcer disease; genital herpes; synthesis; region.
Herpes simplex virus (HSV) type 1 (HSV-1) infection is 
widely prevalent [1, 2]. With its persistent shedding [3, 4], 
HSV-1 is infectious for lifetime, but mostly subclinically 
and asymptomatically [5–7]. When symptomatic, HSV-1 
can cause mild to severe disease [5, 8]. Although infection 
is often manifested as orolabial herpes [5, 8], the virus can 
cause a spectrum of diseases such as herpetic whitlow, gingi-
vostomatitis, meningitis, encephalitis, corneal blindness, and 
neonatal herpes [8, 9].
HSV-1 clinical manifestations are determined by the virus’s 
initial portal of entry [5, 8]. Although it is predominantly 
transmitted through oral shedding [5–7], leading to oral man-
ifestations [5, 8], HSV-1 can be transmitted sexually, leading to 
genital herpes, given the portal of entry [5, 6, 10].
HSV-1 antibody prevalence (seroprevalence) seems to be 
very high globally, with the majority of affected persons sero-
converting by the time they reach puberty [2, 11, 12]. However, 
with continuing improvement in hygiene and living conditions, 
seroprevalence seems to have declined, at least in Western 
countries [11, 13–20]. About half of youth there reach sexual 
debut before being exposed (nonsexually) to HSV-1 and thus 
are at risk of acquiring the infection genitally [5, 21]. Evidence 
indicates a growing role for HSV-1 as a sexually transmitted 
infection (STI) and as a leading, if not the leading, cause of ini-
tial episodes of genital herpes in Western countries [5, 21–25].
Although this striking transition in HSV-1 epidemiology 
in the West is well documented [5, 7, 26], the extent to which 
it is occurring elsewhere is unknown. Understanding HSV-1 
epidemiology in different regions will help characterize the 
HSV-1 burden, oral and genital, and target the most affected 
populations with interventions. To this end, the World Health 
Organization and global partners are spearheading efforts to 
accelerate the development of HSV vaccines [27, 28]. A busi-
ness case is being developed that factors public health needs, 
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pathways of vaccine rollout, impact and cost-effectiveness, and 
return on investment [27]. To inform this effort, it is critical to 
establish current infection levels and trends.
Our overarching goals were to assess HSV-1 seroprevalence 
levels and trends in Asia and the extent to which HSV-1 is 
the cause of genital ulcer disease (GUD) and genital herpes. 
We specifically aimed to (1) methodologically review and 
synthesize available studies on seroprevalence; (2) estimate 
seroprevalence in different populations and ages by pooling 
existing measures; (3) assess seroprevalence temporal trend, 
population-level associations with seroprevalence, and sources 
of between-study heterogeneity; (4) assess the proportion of 
HSV-1 viral detection in clinically diagnosed GUD; and (5) 
assess the proportion of HSV-1 viral detection in clinically 
diagnosed genital herpes. The distinction between the last 2 
aims lies in the denominator—the etiology of GUD includes 
several indications other than HSV-1 infection (diagnosis of 
any GUD) [29], and the etiology of genital herpes includes 
only HSV-1 and HSV type 2 (HSV-2) infections (virological 
diagnosis of herpes) [30].
MATERIALS AND METHODS
Data Sources and Search Strategy
This systematic review was informed by the Cochrane 
Collaboration Handbook [31] and followed the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) guidelines [32]. The PRISMA checklist is in 
Supplementary Table 1.
Available HSV-1 publications in PubMed (from 1950)  and 
Embase (from 1974)  databases were systematically reviewed 
until 22 April 2018. For inclusiveness, broad search criteria were 
used, with MeSH/Emtree terms exploded to cover all subhead-
ings and with no language or year restrictions (Supplementary 
Box 1). Articles in Chinese, English, French, and Japanese were 
reviewed in their original language. Articles in other languages 
were translated. Asia region definition was informed by the 
World Health Organizations definitions for South-East Asia 
and Western Pacific regions [33]. The list of included countries/
territories is in Supplementary Box 2.
Study Selection and Inclusion/Exclusion Criteria
Search results were imported into Endnote (a reference man-
ager), where duplicate publications were identified and 
excluded. Titles and abstracts of remaining records were 
screened for relevance, and full texts of relevant and potentially 
relevant publications were retrieved for additional screening. 
References of articles and reviews were also checked to identify 
further publications that could have been missed.
The inclusion criteria were met for any publication that 
reported HSV-1 seroprevalence measure(s), based on primary 
data using type-specific diagnostic assays such as Western blot 
or type-specific (glycoprotein-G-based) enzyme-linked immu-
nosorbent assays (ELISAs). The inclusion criteria were also 
met for any publication that reported a proportion of HSV-1 
detection by standard viral detection and subtyping methods 
in GUD or genital herpes—to estimate the “etiological” (or 
“associative”) fraction for HSV-1 in these clinical conditions. 
Included studies had to have a sample size of ≥10, regardless of 
outcome measure.
Exclusion criteria included case reports, case series, reviews, 
editorials, letters to editors, commentaries, and qualitative stud-
ies. Measures reporting seroprevalence in <3-month-old infants 
were excluded because of maternal antibodies.
For terminology, a “publication” is a document containing a 
relevant outcome measure, and a “study” or a “measure” indi-
cates all details pertaining to a specific outcome measure—a 
single publication may contribute multiple measures, and mul-
tiple publications of the same data set are deemed a single study.
Data Extraction and Data Synthesis
Extracted variables included author(s), publication title, year(s) 
of data collection, publication year, country of origin, country of 
survey, city, study site, study design, study sampling procedure, 
study population and its characteristics (eg, sex and age), sam-
ple size, HSV-1 outcome measures, and diagnostic assay. Data 
from relevant publications were double extracted by L. K. and 
M. H., with input from R. O.
Extracted overall outcome measures were substituted with 
stratified measures, provided the sample size requirement 
was fulfilled for each stratum. The stratification hierarchy for 
seroprevalence included population type, age bracket, and 
age group, for epidemiological relevance and analysis. In age-
bracket stratification, we aimed to assess seroprevalence in 
adults (≥15  years of age) versus children (<15  years). In age-
group stratification, we aimed to assess seroprevalence growth 
with age (<20, 20–39, or ≥40 years); these strata were optimal 
given reported age-stratified data. Stratification hierarchy for 
GUD and genital herpes proportions included ethnicity, study 
site (eg, hospital or STI clinic), and genital herpes episode (first 
vs recurrent).
Extracted seroprevalence measures were stratified by popu-
lation type into (1) healthy general populations, consisting of 
healthy populations such as blood donors, pregnant women, 
and outpatients with minor health conditions; (2) clinical pop-
ulations, consisting of any population with a major clinical con-
dition, or a condition related (potentially) to HSV-1 infection; 
and (3) other populations, consisting of the remaining popula-
tions not satisfying the above definitions or populations with an 
undetermined risk of acquiring HSV-1, such as persons with 
human immunodeficiency virus infection, sex workers, and 
men who have sex with men.
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Meta-analyses
Meta-analyses were conducted to estimate pooled mean HSV-1 
seroprevalence by population type and by age bracket or group 
and to estimate the pooled mean proportions of HSV-1 detec-
tion in GUD and genital herpes.
Pooled means were estimated using DerSimonian-Laird 
random-effects models [34], provided that ≥3 measures were 
available. This method accounts for sampling variation and het-
erogeneity in effect size (seroprevalence or GUD/genital herpes 
proportion) [34]. The Freeman-Tukey double-arcsine transfor-
mation was used for variance stabilization [35].
The Cochran Q statistic was calculated to assess existence 
of heterogeneity in effect size (P <  .10 indicated heteroge-
neity) [36, 37]. The I2 heterogeneity measure was estimated 
to assess the percentage of between-study variation in effect 
size that is due to actual differences in effect size rather than 
chance [37]. Prediction intervals were calculated to describe 
the heterogeneity in meta-analyses [36, 37]. Meta-analyses 
were performed in R software, version 3.4.1 [38] using the 
meta package [39].
Meta-regression Analyses
Univariable and multivariable random-effects meta-regression 
analyses were conducted to identify predictors of HSV-1 sero-
prevalence (including temporal trend) and sources of between-
study heterogeneity. The log-transformed proportions were 
regressed to estimate risk ratios.
Relevant independent variables were specified a priori: age 
bracket, age group, assay type (Western blot, ELISA, or other), 
country’s income, population type, sample size (<100 vs ≥100 
subjects), sampling method (probability-based vs non–proba-
bility-based sampling), sex, year of data collection, and year of 
publication. Factors associated with seroprevalence at P ≤ .10 
in univariable analysis were included in the final multivari-
able analysis. Factors associated with seroprevalence at P ≤ .05 
in the final multivariable analysis were deemed statistically 
significant.
For the country’s income variable, countries with available data 
were grouped according to the World Bank classification [40]. 
For measures that did not include a year of data collection, 
missing values were imputed using the median of the values cal-
culated by subtracting the year of data collection (when avail-
able) from the year of publication. Meta-regression analyses 
were conducted with Stata/SE software, version 13 [41], using 
the metareg package [42].
Quality Assessment
For diagnostic methods, diversity, and potential issues of sen-
sitivity or specificity [43, 44], we performed quality assessment 
with the support of an expert advisor, Rhoda Ashley-Morrow, 
University of Washington, Seattle. Only publications with suf-
ficiently reliable assays were eligible for inclusion. Study quality 
was further assessed by conducting risk of bias (ROB) assess-
ment (as informed by the Cochrane approach [31]) and preci-
sion assessment.
Studies were categorized as low versus high ROB using 2 
quality domains assessing the rigor of sampling method (prob-
ability based vs otherwise) and response rate (≥80% vs other-
wise). A study was considered to have high (vs low) precision if 
the sample size was ≥100.
RESULTS
Search Results and Scope of Evidence
Figure  1 describes the study-selection process based on 
PRISMA guidelines [32]. A  total of 3517 citations were iden-
tified (988 through PubMed and 2529 through Embase). Of 
these, 528 were relevant or potentially relevant after removal of 
duplicates and screening of titles and abstracts. Eventually, 45 
publications were eligible for inclusion after full-text screening. 
Four additional publications were identified through screening 
of bibliographies of publications and reviews [45–48].
A total of 54 overall seroprevalence measures (distinct over-
all measures in different populations) were extracted, and these 
yielded 182 stratified seroprevalence measures. Eight propor-
tions of HSV-1 detection in GUD and 24 proportions in genital 
herpes were further extracted. Extracted measures originated 
from 13 of 26 Asian countries/territories.
Seroprevalence Overview
Table  1 summarizes the stratified seroprevalence measures. 
The earliest measure was published in 1986. Most measures 
were based on cross-sectional study design (n = 152 measures; 
83.5%), and convenience sampling (n = 150; 82.4%).
Extracted stratified seroprevalence measures varied across 
and within populations, with a range of 11.1%–100% and a 
median of 74.1% (Table 2). The range and median for sero-
prevalence were 11.1%–78.3% and 46.8%, respectively, in 
populations of healthy children (n  =  19), 16.7%–75.9% and 
53.1% in clinical populations of children (n  =  7), 14.1%–
100% and 78.5% in healthy adult populations (n  =  103), 
and 32.1%–95.8% and 67.5% in clinical adult populations 
(n  =  23). Table  2 also includes the ranges and medians for 
further populations.
Pooled Seroprevalence Estimates
Table 2 shows the results of the seroprevalence meta-analyses. 
Among children, the pooled mean seroprevalence was 48.5% 
(n = 19; 95% confidence interval [CI], 37.8%–59.3%) for those 
who were healthy and 54.2% (n  =  7; 40.5%–67.6%) for those 
with clinical conditions. Among adults, the pooled mean was 
77.4% (n = 103; 95% CI, 73.4%–81.1%) for healthy adults and 
67.1% (n = 23; 56.7%–76.8%) for those with clinical conditions. 
Table 2 includes pooled results for further populations. By age 
group, the pooled mean was lowest, at 55.5% (n = 37; 95% CI, 
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47.5%–63.4%), in individuals aged <20 years, followed by 67.9% 
(n = 48; 62.4%–73.3%) in those aged 20–39 and 87.5% (n = 44; 
83%.4–91.1%) in those aged ≥40 years.
Country-specific meta-analyses were conducted for coun-
tries with ≥5 measures for healthy children or adults. For China, 
the pooled means were 61.3% (n = 12; 95% CI, 53.1%–69.2%) 
in children and 93.1% (n  =  23; 90.0%–95.6%) in adults. For 
India and Japan, the pooled means were 66.8% (n = 21; 95% CI, 
58.6%–74.6%) and 68.1% (n = 34; 61.5%–74.6%), respectively, 
in healthy adults.
There was strong evidence for heterogeneity in seropreva-
lence in all meta-analyses (P  <  .003; Table  2). Most variation 
was due to true variation in seroprevalence rather than sam-
pling variation (I2 > 50%). The prediction intervals affirmed 
substantial variation in seroprevalence. Forest plots are shown 
in Supplementary Figure 1.
Predictors of Seroprevalence and Sources of Between-study Heterogeneity
Table  3 shows the results of the regression analyses. In uni-
variable analyses, age bracket, age group, assay type, country’s 
income, population type, and sampling method had P values 
of <.10 and were included in the final multivariable analyses. 
Age group best explained the seroprevalence variation (adjusted 
R2 = 21.1%).
Sample size and sex were not statistically significant. Year of 
data collection and year of publication were also not statisti-
cally significant; strikingly, both risk ratios were 1.0 (95% CI, 
1.0–1.0) supporting a flat seroprevalence over time.
Figure 1. Flow chart of article selection for the systematic review of herpes simplex virus type 1 (HSV-1) in Asia, as adapted from the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) 2009 guidelines [32].
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Table 1. Studies Reporting Herpes Simplex Virus Type 1 Seroprevalence Among Different Populations in Asia
Authors (Year)
Year(s) of Data 
Collection Country Study Site
Study 
Design
Sampling 
Method Population
HSV-1 
Serological 
Assay
Sample 
Size, No.
HSV-1 
Seroprevalence, 
%
Healthy Children Populations (n = 19)
Bogaerts et al (2001) [49] 1996–1998 Bangladesh Outpatient clinic CS Conv 1–12-y-old children WB 79 46.0
Chang (1986) [50] 1984–1986 China Hospital CS Conv 7–12-mo-old infants CFT 31 41.9
Chang (1986) [50] 1984–1987 China Hospital CS Conv 13–24-mo-old 
children
CFT 31 51.6
Chang (1986) [50] 1984–1988 China Hospital CS Conv 24–35-mo-old 
children
CFT 30 43.3
Chang (1986) [50] 1984–1989 China Hospital CS Conv 3–4-y-old children CFT 31 67.7
Chang (1986) [50] 1984–1990 China Hospital CS Conv 5–6-y-old children CFT 31 48.4
Chang (1986) [50] 1984–1991 China Hospital CS Conv 7–8-y-old children CFT 31 71.0
Chang (1986) [50] 1984–1992 China Hospital CS Conv 9–14-y-old children CFT 31 74.2
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 1-y-old children ELISA 90 11.1
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 2-y-old children ELISA 127 14.2
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 3-y-old children ELISA 92 31.5
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 4-y-old children ELISA 84 23.8
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 5–9-y-old children ELISA 111 46.8
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 10–14-y-old children ELISA 92 46.7
Li et al (1990) [52] 1988–1989 China Community CS Conv 1–10-y-old Koreans PHA 16 38.0
Lin et al (2011) [53] 2006 China Community CS RS 5–9-y-old girls ELISA 40 64.9
Lin et al (2011) [53] 2006 China Community CS RS 10–14-y-old girls ELISA 45 78.3
Lin et al (2011) [53] 2006 China Community CS RS 5–9-y-old boys ELISA 75 59.8
Lin et al (2011) [53] 2006 China Community CS RS 10–14-y-old boys ELISA 64 78.0
Healthy Adult Populations (n = 103)
Armelia et al (2012) [54] 2010–2011 Indonesia Hospital CSa Conv Kidney donors Anti-HSV-1 
IgG
23 72.7
Ashley et al (2004) [55] 2000–2001 Thailand Community CS Conv ≥15-y-old women in 
Lampang
WB 98 92.9
Ashley et al (2004) [55] 2000–2001 Thailand Community CS Conv ≥15-y-old women in 
Songkla
WB 90 61.1
Ashley et al (2004) [55] 2000–2001 Vietnam Community CS Conv ≥15-y-old women in 
Hanoi
WB 99 100.0
Ashley et al (2004) [55] 2000–2001 Vietnam Community CS Conv ≥15-y-old women in 
Ho Chi Minh
WB 100 98.0
Bogaerts et al (2001) [49] 1996–1998 Bangladesh Outpatient clinic CS Conv Healthy women ELISA 183 97.0
Bu et al (2015) [45] 2012–2013 China Hospital CC Conv Healthy individuals ELISA 135 78.5
Chang (1986) [50] 1984–1986 China Hospital CS Conv >14-y-old adults CFT 30 93.3
Cowan et al (2003) [56] 1998–2000 India Community CS Conv 15–20-y-old adults ELISA 239b 85.7
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 15–19-y-old adults ELISA 115 53.0
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 20–29-y-old adults ELISA 123 69.9
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 30–39-y-old adults ELISA 129 84.5
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 40–49-y-old adults ELISA 100 94.0
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 50–59-y-old adults ELISA 91 98.9
Chen et al (2013) [51] 2007 Taiwan Community CS Conv 60–69-y-old adult ELISA 122 100
Chen et al (2013) [51] 2007 Taiwan Community CS Conv >70-y-old adults ELISA 96 100
Cowan et al (2003) [56] 1998–2000 India Community CS Conv 20–30-y-old adults ELISA 239b 79.9
Cowan et al (2003) [56] 1998–2000 India Community CS Conv 30–35-y-old adults ELISA 239b 80.0
Cowan et al (2003) [56] 1998–2000 India Community CS Conv 25–40-y-old adults ELISA 239b 84.8
Cowan et al (2003) [56] 1998–2000 India Community CS Conv 40–45-y-old adults ELISA 239b 86.2
Cowan et al (2003) [56] 1998–2000 India Community CS Conv >45-y-old adults ELISA 239b 92.5
Doi et al (2009) [57] 2002 Japan Community CSa RS 18–29-y-old women ELISA 83 45.8
Doi et al (2009) [57] 2002 Japan Community CSa RS 30–39-y-old women ELISA 184 50.5
Doi et al (2009) [57] 2002 Japan Community CSa RS 40–49-y-old women ELISA 198 66.7
Doi et al (2009) [57] 2002 Japan Community CSa RS 50–59-y-old women ELISA 200 79.0
Doi et al (2009) [57] 2002 Japan Community CSa RS 18–29-y-old men ELISA 45 44.4
Doi et al (2009) [57] 2002 Japan Community CSa RS 30–39-y-old men ELISA 129 44.2
Doi et al (2009) [57] 2002 Japan Community CSa RS 40–49-y-old men ELISA 198 49.0
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Authors (Year)
Year(s) of Data 
Collection Country Study Site
Study 
Design
Sampling 
Method Population
HSV-1 
Serological 
Assay
Sample 
Size, No.
HSV-1 
Seroprevalence, 
%
Doi et al (2009) [57] 2002 Japan Community CSa RS 50–59-y-old men ELISA 198 71.7
Hashido et al (1998) [58] NA Japan Community CS Conv <30-y-old men blood 
donors
EIA 12 33.0
Hashido et al (1998) [58] NA Japan Community CS Conv 30–50-y-old men 
blood donors
EIA 17 70.0
Hashido et al (1998) [58] NA Japan Community CS Conv >50-y-old men blood 
donors
EIA 12 92.0
Hashido et al (1998) [58] NA Japan Community CS Conv 20–39-y-old healthy 
women
EIA 20 65.0
Hashido et al (1998) [58] NA Japan Community CS Conv 40–99-y-old healthy 
women
EIA 28 89.0
Hashido et al (1998) [58] NA Japan Community CS Conv >50-y-old healthy 
women
EIA 27 92.5
Hashido et al (1998) [58] NA Japan Community CS Conv Pregnant women 
from Tokyo
EIA 58 47.0
Hashido et al (1998) [58] NA Japan Community CS Conv Pregnant women 
from Kagoshima
EIA 100 61.0
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 20–29-y-old men in 
1973
ELISA 31 64.5
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 30–39-y-old men in 
1973
ELISA 25 76.0
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 40–49-y-old men in 
1973
ELISA 15 86.7
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 20–29-y-old men in 
1983
ELISA 24 37.5
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 30–39-y-old men in 
1983
ELISA 30 76.7
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 40–49-y-old men in 
1983
ELISA 33 90.9
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 20–29-y-old men in 
1993
ELISA 30 33.3
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 30–39-y-old men in 
1993
ELISA 30 56.7
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 40–49-y-old men in 
1993
ELISA 45 75.6
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 20–29-y-old women 
in 1973
ELISA 32 59.4
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 30–39-y-old women 
in 1973
ELISA 33 84.8
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 40–49-y-old women 
in 1973
ELISA 23 100.0
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 20–29-y-old women 
in 1983
ELISA 35 51.4
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 30–39-y-old women 
in 1983
ELISA 36 77.8
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 40–49-y-old women 
in 1983
ELISA 34 97.1
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 20–29-y-old women 
in 1993
ELISA 63 31.7
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 30–39-y-old women 
in 1993
ELISA 54 69.1
Hashido et al (1999) [59] 1973–1993 Japan Community CS Conv 40–49-y-old women 
in 1993
ELISA 41 80.5
Kaur et al (1999) [60] NA India Outpatient clinic CS Conv 16–20-y-old preg-
nant women
EIA 24 50.0
Kaur et al (1999) [60] NA India Outpatient clinic CS Conv 21–25-y-old preg-
nant women
EIA 36 44.4
Kaur et al (1999) [60] NA India Outpatient clinic CS Conv 26–30-y-old preg-
nant women
EIA 34 55.8
Kaur et al (1999) [60] NA India Outpatient clinic CS Conv 31–35-y-old preg-
nant women
EIA 14 14.1
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Authors (Year)
Year(s) of Data 
Collection Country Study Site
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Design
Sampling 
Method Population
HSV-1 
Serological 
Assay
Sample 
Size, No.
HSV-1 
Seroprevalence, 
%
Kaur et al (1999) [60] NA India Outpatient clinic CS Conv >36-y-old pregnant 
women
EIA 12 83.3
Kaur et al (2005) [61] NA India Outpatient clinic CS Conv 16–20-y-old women ELISA 12 50.0
Kaur et al (2005) [61] NA India Outpatient clinic CS Conv 21–25-y-old women ELISA 17 47.1
Kaur et al (2005) [61] NA India Outpatient clinic CS Conv 26–30-y-old women ELISA 18 50.0
Kaur et al (2005) [61] NA India Outpatient clinic CS Conv 31–40-y-old women ELISA 13 46.1
Kaur et al (2005) [61] NA India Outpatient clinic CS Conv 16–20-y-old men ELISA 13 46.1
Kaur et al (2005) [61] NA India Outpatient clinic CS Conv 21–25-y-old men ELISA 20 25.0
Kaur et al (2005) [61] NA India Outpatient clinic CS Conv 26–30-y-old men ELISA 14 71.4
Kaur et al (2005) [61] NA India Outpatient clinic CS Conv 31–40-y-old men ELISA 13 46.1
Li et al (1990) [52] 1988–1989 China Community CS Conv >21-y-old Hans 
Chinese
PHA 78 99.0
Li et al (1990) [52] 1988–1989 China Community CS Conv >21-y-old Koreans PHA 34 97.0
Lin et al (2011) [53] 2006 China Community CS RS 15–19-y-old women ELISA 78 87.5
Lin et al (2011) [53] 2006 China Community CS RS 20–24-y-old women ELISA 101 86.1
Lin et al (2011) [53] 2006 China Community CS RS 25–29-y-old women ELISA 135 93.3
Lin et al (2011) [53] 2006 China Community CS RS 30–34-y-old women ELISA 152 96.7
Lin et al (2011) [53] 2006 China Community CS RS 35–39-y-old women ELISA 154 95.5
Lin et al (2011) [53] 2006 China Community CS RS 40–44-y-old women ELISA 129 98.4
Lin et al (2011) [53] 2006 China Community CS RS 45–49-y-old women ELISA 97 98.0
Lin et al (2011) [53] 2006 China Community CS RS 50–54-y-old women ELISA 101 98.1
Lin et al (2011) [53] 2006 China Community CS RS 55–60-y-old women ELISA 44 97.8
Lin et al (2011) [53] 2006 China Community CS RS 15–19-y-old men ELISA 89 76.5
Lin et al (2011) [53] 2006 China Community CS RS 20–24-y-old men ELISA 93 81.9
Lin et al (2011) [53] 2006 China Community CS RS 25–29-y-old men ELISA 112 86.5
Lin et al (2011) [53] 2006 China Community CS RS 30–34-y-old men ELISA 137 90.4
Lin et al (2011) [53] 2006 China Community CS RS 35–39-y-old men ELISA 144 93.7
Lin et al (2011) [53] 2006 China Community CS RS 40–44-y-old men ELISA 118 97.4
Lin et al (2011) [53] 2006 China Community CS RS 45–49-y-old men ELISA 89 96.7
Lin et al (2011) [53] 2006 China Community CS RS 50–54-y-old men ELISA 82 98.7
Lin et al (2011) [53] 2006 China Community CS RS 55–60-y-old men ELISA 62 98.4
Nasrallah GK, Dargham SR, 
Harfouche M, and Abu-
Raddad LJ (2018, unpub-
lished data)
2013–2016 India Community CS Conv <24-y-old Indian 
men
ELISA 40 40.0
Nasrallah GK, Dargham SR, 
Harfouche M, and Abu-
Raddad LJ (2018, unpub-
lished data)
2013–2016 India Community CS Conv 25–29-y-old Indian 
men
ELISA 49 34.0
Nasrallah GK, Dargham SR, 
Harfouche M, and Abu-
Raddad LJ (2018, unpub-
lished data)
2013–2016 India Community CS Conv 30–34-y-old Indian 
men
ELISA 50 60.0
Nasrallah GK, Dargham SR, 
Harfouche M, and Abu-
Raddad LJ (2018, unpub-
lished data)
2013–2016 India Community CS Conv 35–39-y-old Indian 
men
ELISA 50 36.0
Nasrallah GK, Dargham SR, 
Harfouche M, and Abu-
Raddad LJ (2018, unpub-
lished data)
2013–2016 India Community CS Conv 40–44-y-old Indian 
men
ELISA 50 48.0
Nasrallah GK, Dargham SR, 
Harfouche M, and Abu-
Raddad LJ (2018, unpub-
lished data)
2013–2016 India Community CS Conv 45–49-y-old Indian 
men
ELISA 50 58.0
Nasrallah GK, Dargham SR, 
Harfouche M, and Abu-
Raddad LJ (2018, unpub-
lished data)
2013–2016 India Community CS Conv >50-y-old Indian 
men
ELISA 35 62.0
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Nasrallah GK, Dargham SR, 
Harfouche M, and Abu-
Raddad LJ (2018, unpub-
lished data)
2013–2016 Philippines Community CS Conv <34-y-old Filipino 
men
ELISA 52 84.6
Nasrallah GK, Dargham SR, 
Harfouche M, and Abu-
Raddad LJ (2018, unpub-
lished data)
2013–2016 Philippines Community CS Conv 35–44-y-old Filipino 
men
ELISA 40 82.5
Nasrallah GK, Dargham SR, 
Harfouche M, and Abu-
Raddad LJ (2018, unpub-
lished data)
2013–2016 Philippines Community CS Conv >45-y-old Filipino 
men
ELISA 28 85.7
Patnaik et al (2007) [62] 1985–2007 Thailand Hospital CC Conv Healthy women WB 78 51.3
Schmid et al (1999) [63] 1991–1993 Thailand Hospital CS Conv >21-y-old army men WB 1158 77.9
Shivaswamy et al (2005) 
[64]
2001–2003 India Outpatient clinic CC Conv Healthy individuals ELISA 135 91.8
Yue (1990) [65] 1987–1989 China Outpatient clinic CS Conv Pregnant women ELISA 295 82.0
Zegans et al (1999) [66] 1997 India Hospital CC Conv Controls for a study 
of Mooren ulcer
ELISA 44 64.0
Healthy Mixed-Age Populations (n = 4)
Li et al (1990) [52] 1988–1989 China Community CS Conv 11–20-y-old Hans 
Chinese
PHA 17 94.1
Li et al (1990) [52] 1988–1989 China Community CS Conv 11–20-y-old Koreans PHA 13 85.0
Shen et al (2015) [67] 2007 Taiwan Community CS RS Healthy women ELISA 830 64.5
Shen et al (2015) [67] 2007 Taiwan Community CS RS Healthy men ELISA 581 52.0
Clinical Children Populations (n = 7)
Cowan et al (2003) [56] 1998–2000 India Hospital CS Conv 1–5-y-old children ELISA 90b 40.2
Cowan et al (2003) [56] 1998–2000 India Hospital CS Conv 5–10-y-old children ELISA 90b 68.4
Cowan et al (2003) [56] 1998–2000 India Hospital CS Conv 10–15-y-old children ELISA 90b 75.9
Cowan et al (2003) [56] 1998–2000 Sri Lanka Hospital CS Conv 1–5-y-old children ELISA 144b 40.5
Cowan et al (2003) [56] 1998–2000 Sri Lanka Hospital CS Conv 5–10-y-old children ELISA 144b 53.1
Cowan et al (2003) [56] 1998–2000 Sri Lanka Hospital CS Conv 10–15-y-old children ELISA 144b 74.0
Shymala et al (2008) [68] 2005–2006 India Outpatient clinic CS Conv Infants with congen-
ital cataract
ELISA 18 16.7
Clinical Adult Populations (n = 23)
Armelia et al (2012) [54] 2010–2011 Indonesia Hospital CSa Conv Pre–kidney trans-
plant patients
Anti-HSV-1 
IgG
23 68.2
Bu et al (2015) [45] 2012–2013 China Hospital CC Conv Patients with 
Alzheimer 
disease
ELISA 128 85.2
Hashido et al (1998) [58] NA Japan Community CS Conv <39-y-old patients 
with STD
EIA 10 60.0
Hashido et al (1998) [58] NA Japan Community CS Conv >40-y-old patients 
with STD
EIA 16 81.2
Hashido et al (1998) [58] NA Japan Community CS Conv Pregnant Tokyo 
women with 
HTLV-1
EIA 32 56.0
Hashido et al (1998) [58] NA Japan Community CS Conv Pregnant Kagoshima 
women with 
HTLV-1
EIA 100 83.0
Kaur et al (2006) [69] NA India Outpatient clinic CS Conv Women attending 
an STD clinic
ELISA 52 82.7
Kaur et al (2006) [69] NA India Outpatient clinic CS Conv Women attending 
an STD clinic
ELISA 76 73.7
Patwardhan and Bhalla 
(2016) [70]
NA India Hospital CS Conv Patients with first 
genital herpes
ELISA 21 42.8
Patwardhan and Bhalla 
(2016) [70]
NA India Hospital CS Conv Patients with re-
current genital 
herpes
ELISA 23 65.2
Shivaswamy et al (2005) 
[64]
2001–2003 India Outpatient clinic CC Conv <40-y-old patients in 
an STI clinic
ELISA 111 90.1
Table 1. Continued
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/68/5/757/5055267 by London School of H
ygiene & Tropical M
edicine user on 18 M
arch 2019
HSV-1 Epidemiology in Asia • CID 2019:68 (1 March) • 765
Authors (Year)
Year(s) of Data 
Collection Country Study Site
Study 
Design
Sampling 
Method Population
HSV-1 
Serological 
Assay
Sample 
Size, No.
HSV-1 
Seroprevalence, 
%
Shivaswamy et al (2005) 
[64]
2001–2003 India Outpatient clinic CC Conv ≥40-y-old patients in 
an STI clinic
ELISA 24 95.8
Sun et al (2005) [48] NA China Hospital CS Conv Diabetic inpatients ELISA 206 46.1
Sun et al (2005) [48] NA China Hospital CS Conv Nondiabetic 
inpatients
ELISA 1360 36.3
Theng et al (2006) [71] 2003–2004 Singapore Outpatient clinic CS Conv <29-y-old men ELISA 72 47.2
Theng et al (2006) [71] 2003–2004 Singapore Outpatient clinic CS Conv 30–39-y-old men ELISA 50 52.0
Theng et al (2006) [71] 2003–2004 Singapore Outpatient clinic CS Conv 40–49-y-old men ELISA 41 58.8
Theng et al (2006) [71] 2003–2004 Singapore Outpatient clinic CS Conv >50-y-old men ELISA 37 78.4
Theng et al (2006) [71] 2003–2004 Singapore Outpatient clinic CS Conv <20-y-old female 
patients
ELISA 28 32.1
Theng et al (2006) [71] 2003–2004 Singapore Outpatient clinic CS Conv 20–29-y-old women ELISA 98 49.0
Theng et al (2006) [71] 2003–2004 Singapore Outpatient clinic CS Conv 30–39-y-old women ELISA 40 67.5
Theng et al (2006) [71] 2003–2004 Singapore Outpatient clinic CS Conv >40-y-old women ELISA 32 78.2
Zegans et al (1999) [66] 1999 India Hospital CS Conv Patients with 
Mooren ulcers
ELISA 21 86.0
Clinical Mixed-Age Population (n = 1)
Lee and Lee (2015) [72] NA South Korea Community CSa Conv >11-y-old patients Multiplex 
immu-
noassay
2317 73.8
Other Populations (n = 25)
Chu et al (2006) [73] NA Thailand Hospital CS Conv HIV-infected men ELISA 66 53.0
Chu et al (2006) [73] NA Thailand Hospital CS Conv HIV-infected women ELISA 70 73.0
Cowan et al (2003) [56] 1998–2000 Sri Lanka Outpatient clinic CS Conv 15–20-y-old healthy/
clinical patients
ELISA 622b 74.3
Cowan et al (2003) [56] 1998–2000 Sri Lanka Outpatient clinic CS Conv 20–30-y-old healthy/
clinical patients
ELISA 622b 79.2
Cowan et al (2003) [56] 1998–2000 Sri Lanka Outpatient clinic CS Conv 30–35-y-old health/
clinical patients
ELISA 622b 74.6
Cowan et al (2003) [56] 1998–2000 Sri Lanka Outpatient clinic CS Conv 25–40-y-old healthy/
clinical patients
ELISA 622b 74.5
Cowan et al (2003) [56] 1998–2000 Sri Lanka Outpatient clinic CS Conv 40–45-y-old healthy/
clinical patients
ELISA 622b 77.1
Cowan et al (2003) [56] 1998–2000 Sri Lanka Outpatient clinic CS Conv >45-y-old healthy/
clinical patients
ELISA 622b 82.0
Hashido et al (1998) [58] NA Japan Community CS Conv Female sex workers EIA 70 75.7
Hashido et al (1998) [58] NA Japan Community CS Conv <39-y-old MSM EIA 15 53.3
Hashido et al (1998) [58] NA Japan Community CS Conv >40-y-old MSM EIA 19 97.4
Lin et al (2011) [53] NA China Community CS Conv 18–29-y-old HIV-
infected patients
ELISA 191 94.3
Lin et al (2011) [53] NA China Community CS Conv 30–39-y-old HIV-
infected patients
ELISA 503 92.6
Lin et al (2011) [53] NA China Community CS Conv 40–49-y-old HIV-
infected patients
ELISA 290 89.7
Lin et al (2011) [53] NA China Community CS Conv 50–59-y-old HIV-
infected patients
ELISA 96 85.4
Lin et al (2011) [53] NA China Community CS Conv 60–94-y-old HIV-
infected patients
ELISA 30 93.3
Limpakarnjanara et al 
(1999) [74]
1994 Thailand Community CS Conv >16-y-old female 
sex workers
WB 500 91.0
Neal et al (2011) [75] NA China Community CS Conv Sex workers WB 273 91.9
Qutub and Akhter (2003) 
[76]
NA Bangladesh Community CSa Conv Female sex workers WB 463 92.7
Theng et al (2006) [77] 2003–2004 Singapore Outpatient clinic CS Conv 20–29-y-old sex 
workers
ELISA 146 80.1
Theng et al (2006) [77] 2003–2004 Singapore Outpatient clinic CS Conv 30–39-y-old sex 
workers
ELISA 56 67.9
Theng et al (2006) [77] 2003–2004 Singapore Outpatient clinic CS Conv 40–49-y-old sex 
workers
ELISA 60 68.3
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Table 2. Pooled Mean Estimates for Herpes Simplex Virus Type 1 Seroprevalence Among Different Populations in Asia
Population Type
Outcome 
Measures, Total 
No.
Samples, Total 
No.
HSV-1 Seroprevalence
Pooled 
Mean HSV-1 
Seroprevalence, 
Mean (95% CI)
Heterogeneity Measuresa
Range Median Q (P  Value) I2 (95% CI), %
Prediction 
Interval, 
%
Healthy general populations
 Children 19 1131 11.1–78.3 46.8 48.5 (37.8–59.3) 228.6 (<.001) 92.1 (89.1–94.3) 7.1–91.2
 Adults 103 9514 14.1–100 78.5 77.4 (73.4–81.1) 1841.6 (<.001) 94.5 (93.7–95.1) 34.9–100
 Mixed ages 4 1441 52.0–94.1 74.8 68.9 (56.3–80.3) 36.5 (<.001) 91.8 (82.2–96.2) 16.6–100
All healthy 
general 
populations
126 12 086 11.1–100 73.4 73.1 (68.9–77.1) 2955.4 (<.001) 95.8 (95.3–96.2) 25.3–100
Clinical populations
 Children 7 720 16.7–75.9 53.1 54.2 (40.5–67.6) 78.4 (<.001) 92.3 (86.8–95.6) 11.0–93.9
 Adults 23 2601 32.1–95.8 67.5 67.1 (56.7–76.8) 456.4 (<.001) 95.2 (93.8–96.3) 17.3–100
 Mixed ages 1b 2317 - - 73.8 (71.9–75.6) -b -b -b
 All clinical 
populations
31 5638 16.7–95.8 67.5 64.3 (56.3–71.9) 809.2 (<.001) 96.3 (95.5–97.0) 21.1–97.0
Other populations
 HIV-infected 
patients
8 1476 53.0–94.3 87.6 83.3 (74.0–91.0) 119.4 (<.001) 94.1 (90.6–96.3) 45.7–100
 MSM 3 1774 53.3–97.4 56.5 69.7 (42.9–91.7) 15.5 (<.001) 87.1 (63.2–95.5) 0.0–100
 Sex workers 8 1606 67.9–92.7 84.9 84.1 (77.6–89.7) 63.2 (<.001) 88.9 (80.5–93.7) 59.3–98.6
 Healthy/ 
clinical adult 
populations
6 3732 74.3–82.0 75.9 77.0 (74.4–79.5) 18.0 (.003) 72.3 (36.0–88.0) 68.1–84.8
Age groups
 <20 y 37 3101 11.1–94.1 51.6 55.5 (47.5–63.4) 654.8 (<.001) 94.5 (93.3–95.5) 11.7–94.6
 20–39 y 48 5601 14.1–96.7 67.7 67.9 (62.4–73.3) 784.3 (<.001) 94.0 (92.8–95.0) 23.0–96.0
 ≥40 y 44 4966 48.0–100 89.3 87.5 (83.4–91.1) 633.6 (<.001) 93.2 (91.7–94.4) 55.2–100
 All children 26 1851 11.1–78.3 47.6 50.0 (41.3–58.7) 343.6 (<.001) 92.7 (90.5–94.4) 10.2–89.8
 All adults 151 20 705 14.1–100 77.8 76.5 (73.3–79.6) 3951.1 (<.001) 96.2 (95.8–96.5) 34.2–100
 All mixed-age 
groups
5 3758 52.0–94.1 73.8 70.6 (59.4–80.8) 112.8 (<.001) 96.5 (94.0–97.9) 29.6–98.3
All studies/ 
strata
182 26 314 11.1–100 74.1 72.9 (69.8–75.9) 5038.0 (.001) 96.4 (96.1–96.7) 30.3–99.4
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HSV-1, herpes simplex virus type 1; MSM, men who have sex with men.
aThe Cochran Q statistic is a measure assessing the existence of heterogeneity in effect size; I2, a measure that assesses the magnitude of between-study variation due to actual differences 
in effect size across studies rather than chance; and prediction interval, a measure that estimates the distribution (95% interval) of true effect sizes around the estimated mean.
bNo meta-analysis was done owing to the small number of studies (n < 3).
Authors (Year)
Year(s) of Data 
Collection Country Study Site
Study 
Design
Sampling 
Method Population
HSV-1 
Serological 
Assay
Sample 
Size, No.
HSV-1 
Seroprevalence, 
%
Theng et al (2006) [77] 2003–2004 Singapore Outpatient clinic CS Conv >50-y-old sex 
workers
ELISA 38 89.5
Van Griensven et al (2013) 
[78]
2006–2010 Thailand Community CS Conv >18-y-old MSM ELISA 1740 56.5
Yap et al (2017) [79] NA Malaysia Hospital CS Conv HIV-infected 
patients
ELISA 232 70.7
Abbreviations: CC, case-control; CFT, complement fixation test; Conv, convenience; CS, cross-sectional; EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; HIV, 
human immunodeficiency virus; HSV-1, herpes simplex virus type 1; HTLV-1, human T-lymphotropic virus 1; MSM, men who have sex with men; NA, not available; PHA, passive hemagglu-
tination assay; RS, random sampling; STD, sexually transmitted disease; STI, sexually transmitted infection; WB, Western blot.
aThe actual study design was cohort, but the extracted seroprevalence measure was for the baseline measurement.
bThe study included overall sample size but no sample sizes for individual strata. Each stratum sample size was assumed to be equal to the overall sample size divided by the number of 
strata in the study.
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Two final multivariable analyses were conducted, instead of one, 
because of collinearity between age bracket and age group. The 
model including age bracket, assay type, country’s income, popula-
tion type, and sampling method explained 26.0% of seroprevalence 
variation. Seroprevalence in adults was 1.5-fold (95% CI, 1.3–1.7-
fold) higher than in children. Seroprevalence in upper-middle-in-
come countries was 1.1-fold (95% CI, 1.0–1.3-fold) higher than in 
lower-middle-income countries. No association with assay type, 
population type, and sampling method was found.
The model including age group instead of age bracket 
explained 33.9% of seroprevalence variation and yielded similar 
results. Seroprevalence in individuals aged 20–39 years was 1.3-
fold (95% CI, 1.0–1.5-fold) higher than in individuals <20, and 
for those aged ≥40 years, it was 1.6-fold (1.4–1.9-fold) higher.
Table 3. Univariable and Multivariable Meta-regression Analyses of Herpes Simplex Virus Type 1 Seroprevalence Among Different Populations in Asia
Variable
Outcome 
Measures,
Total No.
Samples,
Total No.
Univariable Analysis Multivariable Analysis
RR
(95% CI) P  Value
Variance 
Explained, 
Adjusted R2, %
Model 1a Model 2b
ARR
(95%CI) P  Value
ARR
(95% CI) P  Value
Age bracket
 Children 26 1851 1.0 … 1.0 … … …
 Adults 151 20 705 1.5 (1.3–1.7) <.001 1.5 (1.3–1.7) <.001 … …
 Mixed ages 5 3758 1.4 (1.1–1.9) .01 18.6 1.5 (1.1–2.0) .006 … …
Age group
 <20 y 37 3101 1.0 … … … 1.0 …
 20–39 y 48 5601 1.2 (1.0–1.4) .008 … … 1.3 (1.0–1.5) <.001
 ≥40 y 44 4966 1.5 (1.3–1.8) <.001 … … 1.6 (1.4–1.9) <.001
 Mixed 53 12 646 1.3 (1.1–1.5) <.001 21.1 … … 1.3 (1.1–1.5) <.001
Assay type
 Western blot 9 2859 1.0 … 1.0 … 1.0 …
 ELISA 137 20 032 0.8 (.6–1.0) .09 0.9 (.8–1.1) .63 0.9 (.7–1.0) .28
 Others 36 3423 0.8 (.6–1.0) .13 0.5 1.0 (.8–1.2) .98 1.0 (.8–1.2) .72
Country’s income
 LMIC 58 8047 1.0 … 1.0 … 1.0 …
 UMIC 55 10 084 1.2 (1.0–1.3) .02 1.1 (1.0–1.3) .01 1.1 (1.0–1.3) .03
 HIC 69 8183 0.9 (.8–1.1) .39 7.1 0.9 (.8–1.2) .13 0.9 (.8–.9) .01
Population type
 Healthy 
general 
populations
126 12 086 1.0 … 1.0 … 1.0 …
 Clinical 
populations
31 5638 0.9 (.8–1.0) .17 1.0 (.8–1.1) .74 1.0 (.9–1.1) .87
 Other 
populations
25 8590 1.1 (1.0–1.3) .07 0.2 1.1 (.9–1.2) .53 1.0 (.9–1.2) .52
Sample sizec
 <100 22 905 1.0 … … … … …
 ≥100 160 25 409 0.9 (.8–1.1) .65 0.0 … … … …
Sampling method
 Probability  
based
33 7104 1.0 … 1.0 … 1.0 …
 Non–proba-
bility based
149 19 210 0.9 (.8–1.0) .04 1.4 1.0 (.9–1.2) .67 1.0 (.8–1.1) .93
Sex
 Female 56 5665 1.0 … … … … …
 Male 55 6422 0.9 (.8–1.1) .29 … … … …
 Mixed 71 14 227 0.9 (.8–1.1) .46 1.4 … … … …
Year of data 
collection
182 26 314 1.0 (1.0–1.0) .84 0.0 … … … …
Year of 
publication
182 26 314 1.0 (1.0–1.0) .58 0.0 … … … …
Abbreviations: ARR, adjusted risk ratio; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; HIC, high-income country; LMIC, lower-middle-income country; RR, risk ratio; 
UMIC, upper-middle-income country. 
aThe variance explained by the final multivariable model 1 (adjusted R2) was 26.0%
bThe variance explained by the final multivariable model 2 (adjusted R2) was 33.9%
cSample size denotes the sample size for each study population found in the original publication.
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HSV-1 Detection in GUD and Genital Herpes
Table 4 summarizes the studies reporting proportion of HSV-1 
detection in GUD (n = 8) and genital herpes (n = 24). Table 5 
shows the results of meta-analyses, with strong evidence for het-
erogeneity. Forest plots are shown in Supplementary Figure 2.
The proportion of HSV-1 detection in GUD ranged between 
0.0% and 28.4%, with a median of 2.5%. The pooled mean pro-
portion was 5.6% (n = 8; 95% CI, 0.8%–13.6%). The proportion 
of HSV-1 detection in genital herpes ranged between 0.0% and 
62.0%, with a median of 16.3%. The pooled mean proportion 
was 18.8% (n = 24; 95% CI, 12.0%–26.7%). HSV-1 was more 
frequently detected in first-episode genital herpes than in 
recurrent genital herpes (Table 4).
Quality Assessment
Outcomes of the quality assessment are shown in Supplementary 
Table  2. Overall, seroprevalence studies were of reasonable 
quality. Of all studies, 70.4% were of high precision, 7.4% had 
low ROB in the sampling method domain, and 38.9% had low 
ROB in the response rate domain. Only 7.4% of studies had 
high ROB in both quality domains.
DISCUSSION
We presented a comprehensive systematic review and syn-
thesis of HSV-1 epidemiology in Asia. Fifty percent of 
children and 75% of adults were infected. Seroprevalence 
increased with age, with most infections acquired in child-
hood. No evidence was found for a temporal trend; sero-
prevalence appeared stable for 3 decades. Nonetheless, 
seroprevalence was 60% higher in those aged ≥40 than in 
those aged <20 years, possibly reflecting a higher exposure 
risk in earlier times, and an earlier transition toward lower 
seroprevalence.
Table 4. Studies From Asia Reporting Proportion of Herpes Simplex Virus Type 1 (HSV-1) Viral Detection in Clinically Diagnosed Genital Ulcer Disease, or 
Proportion of HSV-1 Viral Detection in Clinically Diagnosed Genital Herpes
Authors (Year)
Year(s) of Data 
Collection Country Study Site Study Design
Sampling
Method
HSV-1 
Biological Assay Population
Sample Size, 
No.
Proportion 
of HSV-1 
Detection, %
HSV-1 Detection in Clinically Diagnosed GUD (n = 8)
Chu et al (2006) 
[73]
NA Thailand Hospital CS Conv PCR Patients with gen-
ital ulcers
26 0.0
Chua and 
Cheong 
(1995) [80]
1993 Singapore Outpatient 
clinic
CS Conv CF Male patients 
with primary 
genital ulcers
121 8.3
Chua and 
Cheong 
(1995) [80]
1993 Singapore Outpatient 
clinic
CS Conv CF Female patients 
with primary 
genital ulcers
54 27.8
Chua and 
Cheong 
(1995) [80]
1993 Singapore Outpatient 
clinic
CS Conv CF Male patients 
with recurrent 
genital ulcer
181 1.6
Chua and 
Cheong 
(1995) [80]
1993 Singapore Outpatient 
clinic
CS Conv CF Female patients 
with recurrent 
genital ulcers
24 0.0
Hooi et al 
(2002) [81]
1990–1999 Malaysia Hospital CS Conv IF Patients attending 
a university 
hospital
102 28.4
Hooi et al 
(2002) [81]
1990–1999 Malaysia Outpatient 
clinic
CS Conv IF Patients attending 
an STD clinic
204 3.4
Thirumoorthy 
et al (1986) 
[82]
1984 Singapore Outpatient 
clinic
CS Conv IF Male patients 
with penile 
ulcers
80 0.0
HSV-1 Detection in Clinically Diagnosed Genital Herpes (n = 24)
Cheong et al 
(1990) [83]
1986–1987 Singapore Hospital CS Conv IF First genital 
herpes episode
62 33.9
Chiam et al 
(2010) [84]
1982–2008 Malaysia Hospital CS Conv DFA Malaysian patients 49 61.2
Chiam et al 
(2010) [84]
1982–2008 Malaysia Hospital CS Conv DFA Indian patients 36 50.0
Chiam et al 
(2010) [84]
1982–2008 Malaysia Hospital CS Conv DFA Chinese patients 30 6.7
Chio et al (2015) 
[46]
2014 Singapore Outpatient 
clinic
CS Conv PCR Patients with gen-
ital herpes
193 13.9
Chua and 
Cheong 
(1995) [80]
1993 Singapore Outpatient 
clinic
CS Conv CF Male patients 
with primary 
genital herpes
98 10.2
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As many as 50% of youth reach sexual debut with no pro-
tective antibodies against HSV-1, and thus potentially at risk of 
sexual acquisition. Remarkably, based on virological diagnosis 
studies, there was a substantial role for HSV-1 in genital herpes 
and GUD: 19% of genital herpes cases were due to HSV-1 (as 
opposed to HSV-2), and 6% of GUD cases. These findings sug-
gest an apparently ongoing HSV-1 epidemiological transition, 
as in Western countries [5, 7, 26], possibly mediated by Asia’s 
rapid socioeconomic modernization.
The seroprevalence of HSV-1 varied somewhat by country 
income but was highest in upper-middle-income countries 
(including China). The weaker socioeconomic association 
may relate to recent modernization, say for China, and to 
unexplained low seroprevalence in populations on the Indian 
Authors (Year)
Year(s) of Data 
Collection Country Study Site Study Design
Sampling
Method
HSV-1 
Biological Assay Population
Sample Size, 
No.
Proportion 
of HSV-1 
Detection, %
Chua and 
Cheong 
(1995) [80]
1993 Singapore Outpatient 
clinic
CS Conv CF Female patients 
with primary 
genital herpes
52 28.9
Chua and 
Cheong 
(1995) [80]
1993 Singapore Outpatient 
clinic
CS Conv CF Male patients 
with recurrent 
genital herpes
116 2.5
Chua and 
Cheong 
(1995) [80]
1993 Singapore Outpatient 
clinic
CS Conv CF Female patients 
with recurrent 
genital herpes
19 0.0
Doraisingham 
et al (1987) 
[85]
1984–1986 Singapore Hospital CS Conv IF Genital lesions 
positive for 
HSV
215 21.4
Doraisingham 
et al (1987) 
[85]
1984–1986 Singapore Hospital CS Conv IF Genital HSV 
isolates
49 32.7
Hooi et al 
(2002) [81]
1990–1999 Malaysia Hospital CS Conv IF Patients attending 
a university 
hospital
55 52.7
Hooi et al 
(2002) [81]
1990–1999 Malaysia Outpatient 
clinic
CS Conv IF Patients attending 
an STD clinic
165 4.2
Ishiguro et al 
(1982) [86]
1975–1978 Japan Outpatient 
clinic
CS Conv Nab Patients with gen-
ital herpes
13 53.8
Jacob et al 
(1989) [87]
1983–1986 India Outpatient 
clinic
CS Conv IF Patient with pri-
mary genital 
herpes
10 10.0
Jacob et al 
(1989) [87]
1983–1986 India Outpatient 
clinic
CS Conv IF Patient with re-
current genital 
herpes
42 0.0
Kao et al (1991) 
[88]
1981–1990 Taiwan Hospital CS Conv IF Genital HSV iso-
lates in men
53 0.0
Kao et al (1991) 
[88]
1981–1990 Taiwan Hospital CS Conv IF Genital HSV iso-
lates in women
96a 9.4
Kawana et al 
(1982) [47]
NA Japan Outpatient 
clinic
CS Conv Nab Patients with pri-
mary genital 
herpes
50 62.0
Kawana et al 
(1982) [47]
NA Japan Outpatient 
clinic
CS Conv Nab Patients with re-
current genital 
herpes
49 10.2
Puthavathana 
et al (1998) 
[89]
1994–1996 Thailand Hospital CS Conv IF Women with gen-
ital herpes
75 18.7
Sen et al (2008) 
[90]
1996–2006 Singapore Outpatient 
clinic
CS Conv PCR Patients with gen-
ital herpes
13 53.8
Theng and 
Chan (2004) 
[91]
2001 Singapore Outpatient 
clinic
CS Conv IF First genital 
herpes episode
114 19.3
Theng and 
Chan (2004) 
[91]
2001 Singapore Outpatient 
clinic
CS Conv IF Recurrent genital 
herpes episode
127 4.7
Abbreviations: CF, complement fixation; Conv, convenience; CS, cross-sectional; DFA, direct fluorescent assay; GUD, genital ulcer disease; HSV-1, herpes simplex virus type 1; IF, immuno-
fluorescence; NA, not available; Nab, neutralization antibody test; PCR, polymerase chain reaction; STD, sexually transmitted disease. 
aThis population included a mix of patients with clinically diagnosed genital herpes and patients suspected of a viral infection from whom cervical swab samples were collected (n = 47).
Table 4. Continued
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subcontinent [92]; seroprevalence in adults was 93% in China 
but only 67% in India.
Strikingly, there were no differences in seroprevalence by sex, 
population type, assay type, sampling method, or sample size. 
Age was the only major predictor of seroprevalence. This speaks 
for how HSV-1 is a general-population infection that permeates 
all strata of society. This also demonstrates the ease of sampling 
a representative sample to measure seroprevalence, provided 
that the sample age distribution is representative of the under-
lying population age distribution.
Although seroprevalence was much higher in older than in 
younger cohorts, there was no evidence for a recent temporal 
decline in seroprevalence. This finding may be explained by 
an earlier transition toward lower seroprevalence, or (specula-
tively) by a demographic effect. HSV-1 seroincidence could be 
declining, but with rapidly declining fertility and increasing life 
expectancy rates, the overall seroprevalence could remain sta-
ble, masking the decline in seroincidence. Findings from com-
munity-based Japanese study (performed over 2 decades) seem 
to support such a conjecture; seroprevalence in persons aged 
20–49 years declined by nearly 10% every decade [59].
Our study has limitations. Data availability varied by country 
and no data were identified for 13 mostly lower-income coun-
tries and territories (Bhutan, Brunei, Cambodia, Hong Kong, 
Laos, Macau, Mongolia, Myanmar, Nepal, Papua New Guinea, 
North Korea, Tibet, and Timor-Leste). Seroprevalence showed 
high heterogeneity, but examined predictors explained only 
34% of the variation. Different diagnostic assays were used 
across studies, but assays may vary by sensitivity and specificity 
(eg, ELISA vs Western blot) [43, 44], as well as in the differential 
effect of HSV-2 antibodies—particularly for the classic “relative 
reactivity” methods [93–95]. However, no evidence was found 
for differences in seroprevalence by assay type (Table 3).
Similarly, various diagnostic assays were used for viral 
detection (immunofluorescence, direct fluorescent assay, 
neutralization antibody test, and nucleic acid amplification 
test), but these may differ in HSV-1 detection [96]. HSV-1 
detection in GUD and genital herpes varied across studies, 
possibly reflecting variation in the underlying epidemiology. 
For example, a Malaysian study found >50% HSV-1 detection 
rates in genital herpes in a university hospital, but <5% in a sex-
ually transmitted disease clinic [81], probably reflecting differ-
ences in the populations attending these facilities (general vs 
sexual high-risk population).
In conclusion, HSV-1 seroprevalence remains high in Asia, 
with 50% of children and 75% of adults testing seropositive. 
However, there seems to be an epidemiological transition, 
with lower seroprevalence in younger cohorts. Close to 50% 
of youth reach sexual debut uninfected and potentially at risk 
of sexual acquisition. HSV-1 is possibly playing an influential 
role as an STI, explaining a fraction of GUD and genital her-
pes diagnoses. These findings demonstrate the importance of 
seroprevalence monitoring and GUD/genital herpes etiolog-
ical surveillance, as well as expansion of HSV-1 epidemiol-
ogy research in different age groups and countries; for half of 
countries, no data were available. These findings also highlight 
the need to accelerate HSV-1 vaccine development to control 
transmission and prevent associated clinical and psychosocial 
disease burden.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
Notes
Author contributions. L.  K.  and M.  H.  conducted the systematic 
search, screening, data extraction, and data analysis. R.  O.  contributed 
to data extraction. G. S. contributed to the statistical analysis. H. C. pro-
vided support in study design and data extraction. L. J. A.-R. conceived 
the study and supervised study conduct and analyses. L. K., M. H., and L. 
Table 5. Pooled Proportions in Asia of Herpes Simplex Virus Type 1 Viral Detection in Clinically Diagnosed Genital Ulcer Disease or Genital Herpes
Population Type
Measures,
Total
No.
Samples,
Total
No.
Proportion of HSV-1 
Detection, %
Pooled Proportion 
of HSV-1 
Detection Mean 
(95% CI), %
Heterogeneity Measurea
Range Median Q (P  Value) I2 (95% CI), %
Prediction 
Interval, 
%
Patients with 
clinically 
diagnosed 
GUD
8 792 0.0–28.4 2.5 5.6 (.8–13.6) 91.1 (<.001) 92.3 (87.2–95.4) 0.0–43.7
Patients with 
clinically 
diagnosed 
genital 
herpes
24 1781 0.0–62.0 16.3 18.8 (12.0–26.7) 330.4 (<.001) 93.0 (90.8–94.7) 0.0–62.9
Abbreviations: CI, confidence interval; GUD, genital ulcer disease; HSV-1, herpes simplex virus type 1.
aThe Cochran Q statistic is a measure assessing the existence of heterogeneity in effect size; I2, a measure that assesses the magnitude of between-study variation due to actual differences 
in effect size across studies rather than chance; and prediction interval, a measure that estimates the distribution (95% interval) of true effect sizes around the estimated mean.
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